Dominic B Bernkopf1, Elizabeth D Williams. 1. Monash University, Centre for Cancer Research, Monash Institute of Medical Research, Monash Medical Centre, 246 Clayton Road, Clayton, Victoria, 3168, Australia.
Abstract
BACKGROUND: Loss of erythrocyte membrane protein band 4.1-like 3 (EPB41L3; aliases: protein 4.1B, differentially expressed in adenocarcinoma of the lung-1 (Dal-1)) expression has been implicated in tumor progression. OBJECTIVE: To evaluate literature describing the role of EPB41L3 in tumorigenesis and metastasis, and to consider whether targeting this gene would be useful in the treatment of prostate cancer. METHODS: A literature review of studies describing EPB41L3 and its aliases was conducted. Online databases (NCBI, SwissProt) were also interrogated to collect further data. RESULTS/ CONCLUSION: A growing body of evidence supports a role for loss of EPB41L3 in tumor progression, including in prostate cancer. Therapeutic strategies that could be harnessed to upregulate EPB41L3 gene expression in prostate cancer cells are currently being developed.
BACKGROUND: Loss of erythrocyte membrane protein band 4.1-like 3 (EPB41L3; aliases: protein 4.1B, differentially expressed in adenocarcinoma of the lung-1 (Dal-1)) expression has been implicated in tumor progression. OBJECTIVE: To evaluate literature describing the role of EPB41L3 in tumorigenesis and metastasis, and to consider whether targeting this gene would be useful in the treatment of prostate cancer. METHODS: A literature review of studies describing EPB41L3 and its aliases was conducted. Online databases (NCBI, SwissProt) were also interrogated to collect further data. RESULTS/ CONCLUSION: A growing body of evidence supports a role for loss of EPB41L3 in tumor progression, including in prostate cancer. Therapeutic strategies that could be harnessed to upregulate EPB41L3 gene expression in prostate cancer cells are currently being developed.
Authors: Christian Huisman; Monique G P van der Wijst; Fahimeh Falahi; Juul Overkamp; Gellért Karsten; Martijn M Terpstra; Klaas Kok; Ate G J van der Zee; Ed Schuuring; G Bea A Wisman; Marianne G Rots Journal: Epigenetics Date: 2015-04-01 Impact factor: 4.528
Authors: Robert D Busam; Ann-Gerd Thorsell; Alex Flores; Martin Hammarström; Camilla Persson; Björn Öbrink; B Martin Hallberg Journal: J Biol Chem Date: 2010-12-03 Impact factor: 5.157
Authors: Wolfgang A Schulz; Marc Ingenwerth; Carolle E Djuidje; Christiane Hader; Jörg Rahnenführer; Rainer Engers Journal: BMC Cancer Date: 2010-09-22 Impact factor: 4.430
Authors: Nataša Vasiljević; Dorota Scibior-Bentkowska; Adam R Brentnall; Jack Cuzick; Attila T Lorincz Journal: Gynecol Oncol Date: 2014-02-06 Impact factor: 5.482